Enlivex Therapeutics Current Valuation vs. Book Value Per Share

ENLV Stock  USD 1.20  0.01  0.83%   
Based on Enlivex Therapeutics' profitability indicators, Enlivex Therapeutics may not be well positioned to generate adequate gross income at the present time. It has a very high chance of underperforming in January. Profitability indicators assess Enlivex Therapeutics' ability to earn profits and add value for shareholders. Price To Sales Ratio is likely to drop to 39.01 in 2024. EV To Sales is likely to drop to 37.08 in 2024. At this time, Enlivex Therapeutics' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Income Tax Expense is likely to climb to about 4.5 M in 2024, despite the fact that Income Before Tax is likely to grow to (27.6 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.70.79
Fairly Down
Slightly volatile
For Enlivex Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Enlivex Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Enlivex Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Enlivex Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Enlivex Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.98)
Return On Assets
(0.27)
Return On Equity
(0.61)
The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Enlivex Therapeutics Book Value Per Share vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Enlivex Therapeutics's current stock value. Our valuation model uses many indicators to compare Enlivex Therapeutics value to that of its competitors to determine the firm's financial worth.
Enlivex Therapeutics is rated below average in current valuation category among its peers. It is rated below average in book value per share category among its peers . The ratio of Current Valuation to Book Value Per Share for Enlivex Therapeutics is about  1,636,244 . At this time, Enlivex Therapeutics' Book Value Per Share is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Enlivex Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Enlivex Current Valuation vs. Competition

Enlivex Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Information Technology industry is currently estimated at about 5.28 Billion. Enlivex Therapeutics adds roughly 2.65 Million in current valuation claiming only tiny portion of equities under Information Technology industry.

Enlivex Book Value Per Share vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enlivex Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
2.65 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Enlivex Therapeutics

Book Value per Share

 = 

Common Equity

Average Shares

 = 
1.62 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Enlivex Book Value Per Share Comparison

Enlivex Therapeutics is currently under evaluation in book value per share category among its peers.

Enlivex Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Enlivex Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Enlivex Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Enlivex Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Enlivex Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income1.3 M1.3 M
Income Tax Expense4.2 M4.5 M
Operating Income-29.4 M-27.9 M
Income Before Tax-29.1 M-27.6 M
Total Other Income Expense Net327 K343.4 K
Net Loss-29.1 M-27.6 M
Net Interest Income1.6 M1.6 M
Interest Income1.6 M1.6 M
Net Loss-27.2 M-25.8 M
Net Loss-28 M-26.6 M
Change To Netincome6.4 M6.7 M
Net Loss(1.56)(1.64)
Income Quality 0.81  0.68 
Net Income Per E B T 1.23  0.83 

Enlivex Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Enlivex Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Enlivex Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Enlivex Therapeutics' important profitability drivers and their relationship over time.

Use Enlivex Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enlivex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enlivex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Enlivex Therapeutics Pair Trading

Enlivex Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Enlivex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enlivex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enlivex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enlivex Therapeutics to buy it.
The correlation of Enlivex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enlivex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enlivex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enlivex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Enlivex Therapeutics position

In addition to having Enlivex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Alternative Energy Thematic Idea Now

Alternative Energy
Alternative Energy Theme
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Enlivex Stock Analysis

When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.